Ellicott City, MD, United States of America

Samuel Ray Denmeade

USPTO Granted Patents = 24 


 

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 246(Granted Patents)


Location History:

  • Baltimore, MD (US) (2001 - 2003)
  • Ellicot City, MD (US) (2007 - 2015)
  • Ellicott City, MD (US) (2003 - 2023)

Company Filing History:


Years Active: 2001-2023

Loading Chart...
Loading Chart...
Loading Chart...
24 patents (USPTO):Explore Patents

Samuel Ray Denmeade: Pioneering Innovations in Cancer Treatment

Introduction

Samuel Ray Denmeade is a distinguished inventor based in Ellicott City, MD, known for his groundbreaking contributions in the field of cancer treatment. With a prolific portfolio of 24 patents, Denmeade has focused on developing innovative therapeutics aimed at improving patient outcomes in oncology.

Latest Patents

Denmeade's latest patents include a range of compounds described as emetine derivatives, which can act as prodrugs that selectively release emetine in specific cellular conditions. These compounds incorporate a blocking group onto the emetine molecule, allowing it to activate through hydrolysis in cancer or tumor microenvironments. This innovative approach reduces cytotoxicity compared to standard emetine, making it less harmful to non-cancerous cells. His work encompasses treatments for various cancers, including breast, prostate, lung cancer, and leukemia.

Additionally, Denmeade has developed a series of albumin-proaerolysin prodrugs aimed at treating cancer more effectively. His prodrug compositions include those activated by prostate-specific antigen (PSA), integrating advanced methodologies to improve targeting and efficacy in cancer therapies.

Career Highlights

Denmeade's career includes significant positions at notable institutions such as The Johns Hopkins University and Genspera, Inc. His work has not only contributed to academic advancements but also brought innovative cancer treatments closer to clinical application.

Collaborations

Throughout his career, Denmeade has collaborated with esteemed colleagues, including John Tod Isaacs and Hans Lilja. These partnerships have further enriched his research and expanded the impact of his inventions in the field of oncology.

Conclusion

Samuel Ray Denmeade exemplifies the spirit of innovation in cancer research and treatment. His extensive portfolio of patents reflects a commitment to discovering novel therapies that could significantly improve cancer patient outcomes. With ongoing collaborations and advancements in his work, Denmeade continues to pave the way for future innovations in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…